Werewolf Therapeutics

Watertown, US · 7 known investors

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.

BiotechHealthtechMedical Devices

Founders & leadership

Daniel J. HicklinFounder, President, Chief Executive Officer, and Board member

Luke EvninCo-founder, Board member (Chairman)

Daniel HicklinExecutive Officer, Director

Alon LazarusDirector

David CordoExecutive Officer

Christoph WestphalDirector

Briggs MorrisonDirector

Sakae AsanumaDirector

Investors · 7

DC Investment PartnersMcLean · $10M

K2 HealthVenturesBoston · $10M – $100M

Longwood FundBoston

MPM BioImpactBoston · $1M – $15M

RA CapitalBostonvia Derek DiRocco · board

Taiho Ventures, LLCMenlo Park

MPM Capitalreportedvia Luke Evnin · board

Reported raises · per SEC filings

Form D private placements

▶$72.1MraisedJan 2021 · 19 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Luke EvninDirector
Briggs MorrisonDirector
Daniel HicklinExecutive Officer, Director
Sakae AsanumaDirector
Alon LazarusDirector
Elise WangDirector
David CordoExecutive Officer
Derek DiRoccoDirector

Offering amount: $72.1M
Amount sold: $72.1M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$56.2MraisedAug 2020 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Luke EvninDirector
Daniel HicklinExecutive Officer, Director
Alon LazarusDirector
David CordoExecutive Officer
Christoph WestphalDirector
Briggs MorrisonDirector
Sakae AsanumaDirector

Offering amount: $56.2M
Amount sold: $56.2M
First sale: Aug 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.